Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...

The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

Zura Bio’s CEO and director Robert Lisicki discusses how his path to leadership taught him the importance of building a team ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

The survey reveals how financial anxiety has become an everyday occurrence affecting everyday health through stress, ...

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Vinay Prasad, MD, MPH, who was appointed to run the FDA's Center for Biologics Evaluation and Research in May, has departed ...